Purespring's Groundbreaking Posters at ASN Kidney Week 2025
Purespring Therapeutics is excited to announce that it will showcase groundbreaking research during the American Society of Nephrology (ASN) Kidney Week 2025. This extraordinary event is set to take place from November 5 to 9, 2025, in Houston, Texas. Attendees can look forward to three scientifically rich posters focused on advancing nephrology and gene therapies aimed at preserving kidney function.
Phase I/II Trial of PS-002
The first poster highlights the study design and methodology of Purespring's Phase I/II trial for PS-002, an innovative AAV-based gene therapy targeting complement factor I delivery to podocytes in patients suffering from IgA nephropathy (IgAN). This pioneering approach has the potential to address complement-driven glomerular conditions directly where the disease occurs, while maintaining systemic complement activation. A single dose of PS-002 is anticipated to provide long-term benefits, enabling podocytes to produce therapeutic factors locally when needed.
Engaging Patients and Caregivers
Feedback on Gene Therapy Study Concepts
The second poster focuses on insights gathered from feedback sessions involving IgAN patients and their caregivers in both the US and the UK. Conducted in collaboration with the IgA Nephropathy Foundation and the National Institute for Health and Care Research, these sessions aimed to refine clinical trial design for future therapies, including PS-002. The enthusiasm expressed for a simplified, 'one-and-done' treatment model illustrates a strong demand for innovative approaches to gene therapy in nephrology.
Real-World Epidemiological Insights
Epidemiological Data on NPHS2 Variants
Purespring also joins forces with the University of Bristol on the third poster, which presents comprehensive data on NPHS2 pathogenic variants derived from the analysis of over 1.2 million genomes. This research aims to estimate the frequency of pathogenic genotypes across various populations, including the US, UK, Europe, and Japan. Additionally, the study provides insights into how these variants influence disease manifestation and progression in conditions such as focal segmental glomerulosclerosis (FSGS) and steroid-resistant nephrotic syndrome (SRNS).
Purespring's Commitment to Innovation
Purespring is actively pushing the boundaries in precision nephrology with its commitment to developing transformative genetic therapies. The company’s GlomThera™ platform allows for direct genetic therapy delivery to the affected kidney cells, representing a novel route for intervening in kidney diseases. Purespring's approach is not only about addressing existing conditions but is focused on reshaping the future of kidney health.
Looking Ahead
In a significant development, Purespring recently secured UK Clinical Trial Authorisation for its Phase I/II trial of PS-002, marking a pivotal step forward in its mission to improve outcomes for patients with IgAN. This authorization follows earlier achievements, including obtaining IND clearance from the FDA, which underscores the company's dedication to rigorous clinical standards and findings.
For more updates and detailed information about Purespring, including ongoing and future initiatives, stay connected through their official website and LinkedIn page. By focusing on unmet medical needs within nephrology, Purespring aims to inform and empower patients, healthcare professionals, and the broader community about the advancements in kidney disease treatments.
Frequently Asked Questions
What is the significance of Purespring's presentation at Kidney Week 2025?
Purespring's presentations at Kidney Week highlight groundbreaking research in gene therapy for kidney diseases, showcasing their commitment to innovation and patient engagement.
What are the key focuses of Purespring's research?
The key focuses include gene therapy design, patient feedback on clinical trials, and real-world epidemiological data on nephrology conditions.
Who are the main presenters at the poster sessions?
Fredrik Erlandsson, the Chief Medical Officer of Purespring, will present the key findings during the poster sessions.
What is PS-002 and its role in nephrology?
PS-002 is an AAV-based gene therapy designed to deliver the complement factor I to podocytes, targeting IgA nephropathy and helping to manage the disease effectively.
How is Purespring addressing unmet needs in kidney disease treatment?
Purespring is developing innovative, patient-centered therapies aimed at modifying disease progression, offering new hope to patients with kidney conditions.
